ResMed

RMD

Market cap $40.2B

274.51 USD

-0.87

0.32%

At close Updated Aug 29, 4:00 PM EDT

Pre-market

After hours

274.51

0.00

0%

1 day

-0.32%

5 days

-6.43%

1 month

-1.15%

3 months

11.99%

6 months

17.55%

Year to date

20.15%

1 year

12.89%

5 years

51.85%

10 years

428.51%

About: ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

Employees: 9,980

Healthcare Medical Instruments & Supplies

0

Funds holding %

of 7,446 funds

0

Analysts bullish %

of 6 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

64% more first-time investments, than exits

New positions opened: 120 | Existing positions closed: 73

14% more funds holding in top 10

Funds holding in top 10: 7 [Q1] → 8 (+1) [Q2]

14% more capital invested

Capital invested by funds: $20.8B [Q1] → $23.7B (+$2.83B) [Q2]

3% more funds holding

Funds holding: 871 [Q1] → 900 (+29) [Q2]

9% more repeat investments, than reductions

Existing positions increased: 346 | Existing positions reduced: 317

0.85% less ownership

Funds ownership: 63.44% [Q1] → 62.59% (-0.85%) [Q2]

49% less call options, than puts

Call options by funds: $76.1M | Put options by funds: $149M

See Fund Rankings

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$270

-2% downside

Avg. target

$292

6% upside

High target

$325

18% upside

6 analyst ratings

4 positive

67%

2 neutral

33%

0 negative

0%

Mizuho Anthony Petrone	5% upside $290	Outperform Maintained	1 Aug 2025
Stifel Jonathan Block	1% downside $270	Hold Maintained	1 Aug 2025
RBC Capital Craig Wong-Pan	9% upside $300	Outperform Maintained	1 Aug 2025
UBS Laura Sutcliffe	18% upside $325	Buy Maintained	1 Aug 2025
Keybanc Brett Fishbin	8% upside $298	Overweight Maintained	1 Aug 2025
Piper Sandler Adam Maeder	1% downside $270	Neutral Maintained	1 Aug 2025

See Analyst Rankings

Financial journalist opinion

Based on 14 articles about RMD published over the past 30 days

Zacks Investment Research

Here's Why ResMed (RMD) is a Strong Growth Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Here's Why ResMed (RMD) is a Strong Growth Stock

Obstructive Sleep Apnea Expected to Affect Nearly 77 million U.S. Adults by 2050, New Resmed Study Finds

SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced the publication of a landmark study in The Lancet Respiratory Medicine projecting a significant rise in obstructive sleep apnea (OSA) in the United States over the next three decades due to a variety of factors, including an aging population and increasing body mass index (BMI). The study estimates that by 2050, OSA will affect nearly 77 million U.S. adults, representing a relative1 increase of nearly 35% from 2020 and impacting 46% of adults aged 30-69.

Obstructive Sleep Apnea Expected to Affect Nearly 77 million U.S. Adults by 2050, New Resmed Study Finds

ResMed: A Dividend Opportunity In The MedTech Space As The Company Grows

For my first rating of ResMed, I'm calling a buy, agreeing with today's consensus from Wall St. and more confident than the quant system, which said hold. Key upside factors are new business acquisitions and FDA approvals, proven demand momentum so far, and revenue diversification along with strong profit margins in its peer group. RMD is a proven dividend grower over 10 years while also having an attractive balance sheet risk profile with a low D/E ratio.

ResMed: A Dividend Opportunity In The MedTech Space As The Company Grows

Resmed Announces Election of Nicole Mowad-Nassar to Board of Directors and Upcoming Retirement of Rich Sulpizio

SAN DIEGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced the election of Nicole Mowad-Nassar to its board of directors, effective August 15, 2025. The company also announced that board member Rich Sulpizio is thanked for two decades of contributions to Resmed, and will retire from the board, not standing for reelection at the 2025 Annual Meeting of Stockholders, scheduled for November 19, 2025.

Resmed Announces Election of Nicole Mowad-Nassar to Board of Directors and Upcoming Retirement of Rich Sulpizio

Zacks Investment Research

Why ResMed (RMD) is a Top Momentum Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Why ResMed (RMD) is a Top Momentum Stock for the Long-Term

Zacks Investment Research

Why ResMed (RMD) is a Top Growth Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Why ResMed (RMD) is a Top Growth Stock for the Long-Term

Top 50 High-Quality Dividend Stocks For August 2025

My investable universe of 50 high-quality dividend growth stocks aims to identify attractive opportunities based on valuation and future return potential. Currently, 20 stocks offer an estimated future return of at least 10%, with 10 of these also appearing potentially undervalued by my Free Cash Flow model. Top highlighted stocks like MKTX, RACE, RMD, MSCI, and TTC combine strong free cash flow growth, attractive valuations, and double-digit return estimates.

Top 50 High-Quality Dividend Stocks For August 2025

ResMed Analysts Increase Their Forecasts After Strong Q2 Earnings

Resmed Inc RMD reported better-than-expected earnings for the second quarter on Thursday.

ResMed Analysts Increase Their Forecasts After Strong Q2 Earnings

Zacks Investment Research

Resmed Q4 Earnings & Revenues Beat Estimates, Stock Up, Margins Climb

RMD tops Q4 earnings and revenue estimates with double-digit growth, rising margins and strong global device demand.

Resmed Q4 Earnings & Revenues Beat Estimates, Stock Up, Margins Climb

ResMed Inc. (RMD) Q4 2025 Earnings Call Transcript

ResMed Inc. (NYSE:RMD ) Q4 2025 Earnings Conference Call July 31, 2025 4:30 PM ET Company Participants Brett A. Sandercock - Chief Financial Officer Michael J.

ResMed Inc. (RMD) Q4 2025 Earnings Call Transcript

See News Rankings

Charts implemented using Lightweight Charts™